Entera Bio Ltd. ENTX, Orphazyme A/S ORPH and Bellerophon Therapeutics, Inc. BLPH are among the biggest biopharma movers Wednesday.
Entera Bio Climbs On Positive Data For Oral Bone-building Drug: Entera Bio announced the final six-month bone mineral density, or BMD, results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis, showing the most important BMD endpoint — change in lumbar spine BMD after six months — was met.
"There were statistically significant dose-related trends in the increases in LS BMD as well as femoral neck and total hip BMD, with the largest increases observed in subjects treated with EB613 2.5 mg," Entera said.
EB613 is an oral formulation of human parathyroid hormone, positioned to be the first oral bone building product to treat osteoporosis patients.
The company said it is looking ahead to an end-of-Phase 2 meeting with the FDA.
Entera Bio is a biopharma developing orally delivered large molecule and biologic therapeutics.
Entera Bio was rallying 64.14% to $7.37.
Orphazyme Reacts to Goldman's Brief Stake Build Above 5%: Danish biotech Orphazyme, which recently faced a regulatory setback, said the Goldman Sachs Group, Inc GS briefly increased its stake in Orphazyme above 5%.
As of June 16, Goldman's aggregate holding of shares and financial instruments increased to 5.58% and by the very next day, the financial giant's stake fell below 5%.
Orphazyme is a late-stage biopharma using heat shock protein response for the treatment of rare diseases.
Orphazyme shares were jumping 32.16% to $7.89.
Bellerophon Moves Amid Lack of News: Bellerophon shares breached the $5 barrier for the first time since early April, with volume about 50 times more than the 3-month average.
There are no apparent catalyst to explain the stock move, given the company has not put out any release.
Bellerophon is clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases. The company is developing three product candidates under its INOpulse platform, a proprietary pulsatile nitric oxide drug delivery system, for the treatment of pulmonary hypertension associated with interstitial lung disease, chronic obstructive pulmonary disease and sarcoidosis.
Bellerophon shares were advancing 28.59% to $5.25.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.